A comparative study of Fas and Fas-ligand expression during melanoma progression

British Journal of Dermatology

Volumn 143, Issue 2, 2000, Pages 307-312

  Soubrane, C ^a   Mouawad, R ^a   Antoine, E C ^a   Verola, O ^b   Gil Delgado, M ^a   Khayat, D ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b S Louis Hosp 1 Av Claude V   (France)

Author keywords

Apoptosis; CD95 Fas receptor; Fas ligand; Malignant melanoma

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPATHOLOGY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANTIGENS, CD95; ANTIGENS, NEOPLASM; APOPTOSIS; DISEASE PROGRESSION; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; LIGANDS; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; SKIN NEOPLASMS;

EID: 0033839180     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03655.x     Document Type: Article

References (23)

1. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance
2. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
3. Human lung carcinomas express Fas ligand
4. Up-regulation of Fas (APO-1/ CD95) ligand and down-regulation of Fas expression in human esophageal cancer
5. Immunohistochemical study of Fas. Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer
6. Fas expression and function in normal and malignant breast cell lines
7. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
8. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing
9. Human melanoma cells do not express Fas (Apo-1/CD95) ligand
10. Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies
11. Influence of interleukin-6 on apoptosis through CD95 (Fas/APO-1) receptor expression in melanoma
12. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes
13. Preparing suspensions of single cells
14. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma
15. Fas ligand is expressed in normal skin and in some cutaneous malignancies
16. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors
17. Predominant expression of Fas (CD95) Ligand in metastatic melanoma revealed by longitudinal analysis
18. Expression of CD95 ligand in melanocytic lesions as a diagnostic marker
19. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas
20. Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocyte and squamous cell carcinoma cell lines
21. Resistance to Fas-mediated apoptosis in human hepatoma cells
22. Alteration of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma